## Elabela(19-32)

MedChemExpress

®

Cat. No.:	HY-P2106				
CAS No.:	1886973-05-2				
Molecular Formula:	C <sub>75</sub> H <sub>119</sub> N <sub>25</sub> O <sub>17</sub> S <sub>2</sub>				
Molecular Weight:	1707.03		{Glp}RRCMPLHSRVPFP		
Target:	Apelin Receptor (APJ); Arrestin				
Pathway:	GPCR/G Protein				
Storage:	Sealed stora	age, away	r from moisture		
	Powder	-80°C	2 years		
		-20°C	1 year		
	* In solvent	:-80°C,6			

## SOLVENT & SOLUBILITY

In Vitro	H <sub>2</sub> O : 100 mg/mL (58.58 mM; Need ultrasonic)					
		Solvent Mass Concentration	1 mg	5 mg	10 mg	
	Preparing Stock Solutions	1 mM	0.5858 mL	2.9291 mL	5.8581 mL	
		5 mM	0.1172 mL	0.5858 mL	1.1716 mL	
		10 mM	0.0586 mL	0.2929 mL	0.5858 mL	
	Please refer to the so	lubility information to select the app	propriate solvent.			
In Vivo	1. Add each solvent o Solubility: 50 mg/i	one by one: PBS mL (29.29 mM); Clear solution; Need	ultrasonic			

Description	Elabela(19-32) is an active fragment of ELABELA (ELA) that binds to apelin receptor (APJ). Elabela(19-32) activates the $G_{\alpha i1}$ and $\beta$ -arrestin-2 signaling pathways with EC <sub>50</sub> s of 8.6 nM and 166 nM. Elabela(19-32) induces receptor internalization and reduces arterial pressure, exerts positive inotropic effects on the heart <sup>[1]</sup> .					
IC <sub>50</sub> & Target	IC50: 8.6 nM (G_{\alpha i1}) and 166 nM (β-arrestin-2)^{[1]}					
In Vitro	Elabela(19-32) (analogue 3) has a K <sub>i</sub> of 0.93 nM for binding of radioligand apelin-13[Glp <sup>65</sup> , Nle <sup>75</sup> , Tyr <sup>77</sup> ][ <sup>125</sup> I] <sup>[1]</sup> . Elabela(19-32) has an EC <sub>50</sub> of 36 nM in HEK293 cells transiently expressing the HA-hAPJ receptor. Elabela(19-32) is slightly less potent than apelin-13 and ELA to elicit receptor internalization <sup>[1]</sup> . Elabela(19-32) (0.001 to 0.3 nM) has an EC <sub>50</sub> of 1.5 pM in inducing changes in left ventricular developed pressure (LVDP) on the Langendorff perfused isolated rat heart <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.					

Product Data Sheet

In Vivo

Elabela(19-32) (analogue 3) is rapidly metabolized in rat plasma (t<sub>1/2</sub><2 min)<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Free Radic Biol Med. 2022 Feb 2;S0891-5849(22)00031-4.
- J Cardiovasc Transl Res. 2022 Feb 16;1-13.
- Cell Stress Chaperones. 2022 Dec 13.

See more customer validations on www.MedChemExpress.com

## REFERENCES

[1]. Alexandre Murza, et al. Discovery and Structure-Activity Relationship of a Bioactive Fragment of ELABELA That Modulates Vascular and Cardiac Functions. J Med Chem. 2016 Apr 14;59(7):2962-72.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA